NASDAQ:AZRX - AzurRx BioPharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.38 -0.08 (-2.31 %)
(As of 06/25/2018 12:01 PM ET)
Previous Close$3.35
Today's Range$3.30 - $3.38
52-Week Range$2.25 - $5.25
Volume753 shs
Average Volume83,798 shs
Market Capitalization$58 million
P/E RatioN/A
Dividend YieldN/A
Beta0.12
AzurRx BioPharma logoAzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.

Receive AZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AZRX
CUSIPN/A
Phone646-699-7855

Debt

Debt-to-Equity RatioN/A
Current Ratio0.64
Quick Ratio0.64

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book24.14

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-11,090,000.00
Net MarginsN/A
Return on Equity-468.72%
Return on Assets-181.43%

Miscellaneous

Employees13
Outstanding Shares16,760,000

The Truth About Cryptocurrencies

AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions

What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

How were AzurRx BioPharma's earnings last quarter?

AzurRx BioPharma Inc (NASDAQ:AZRX) announced its quarterly earnings data on Monday, May, 14th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.11. View AzurRx BioPharma's Earnings History.

When is AzurRx BioPharma's next earnings date?

AzurRx BioPharma is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for AzurRx BioPharma.

What price target have analysts set for AZRX?

1 brokers have issued 12 month price targets for AzurRx BioPharma's stock. Their predictions range from $6.00 to $6.00. On average, they expect AzurRx BioPharma's stock price to reach $6.00 in the next twelve months. View Analyst Ratings for AzurRx BioPharma.

Who are some of AzurRx BioPharma's key competitors?

Who are AzurRx BioPharma's key executives?

AzurRx BioPharma's management team includes the folowing people:
  • Mr. Johan M. Spoor, Pres, CEO & Director (Age 46)
  • Mr. Maged S. Shenouda R.Ph, MBA, CFO & Director (Age 54)
  • Mr. Daniel Dupret, Chief Scientific Officer (Age 62)
  • Dr. Mathieu Schué Ph.D., Head of Laboratory
  • Dr. James E. Pennington, Chief Medical Officer (Age 75)

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an initial public offering on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

Has AzurRx BioPharma been receiving favorable news coverage?

News headlines about AZRX stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AzurRx BioPharma earned a coverage optimism score of 0.17 on Accern's scale. They also gave news articles about the company an impact score of 44.64 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are AzurRx BioPharma's major shareholders?

AzurRx BioPharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Parsons Capital Management Inc. RI (1.97%). View Institutional Ownership Trends for AzurRx BioPharma.

Which institutional investors are buying AzurRx BioPharma stock?

AZRX stock was purchased by a variety of institutional investors in the last quarter, including Parsons Capital Management Inc. RI. View Insider Buying and Selling for AzurRx BioPharma.

How do I buy shares of AzurRx BioPharma?

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AzurRx BioPharma's stock price today?

One share of AZRX stock can currently be purchased for approximately $3.38.

How big of a company is AzurRx BioPharma?

AzurRx BioPharma has a market capitalization of $58 million. AzurRx BioPharma employs 13 workers across the globe.

How can I contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]


MarketBeat Community Rating for AzurRx BioPharma (AZRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote "Outperform" if you believe AZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.